Last Update 29 Apr 26

Fair value Increased 7.61%

CAPR: August PDUFA Cardiac Data Will Drive Bullish 2026 Approval Setup

Narrative Update: Capricor Therapeutics

The updated analyst price target framework for Capricor Therapeutics moves from a prior fair value of $50.80 to $54.67. This reflects analysts' use of higher projected revenue growth, wider profit margins and a higher future P/E multiple following recent positive deramiocel data, FDA review progress and a series of target increases across the Street.

Analyst Commentary

Recent Street research on Capricor Therapeutics has been heavily focused on deramiocel, the evolving FDA review timeline, and the implications of new Phase 3 HOPE-3 data for Duchenne muscular dystrophy. Price targets in the research set provided range from US$41 to US$63, with multiple upward revisions tied to the regulatory and clinical updates.

Bullish Takeaways

Bullish analysts point to FDA acceptance of the updated Biologics License Application for deramiocel and the August 22 PDUFA date as key milestones that underpin higher valuation frameworks, including raised price targets into the US$50 to US$60 range.
Additional positive Phase 3 HOPE-3 data in Duchenne muscular dystrophy is seen as reinforcing the clinical story, which bullish analysts tie directly to higher revenue potential assumptions and wider margin outlooks in their models.
Some bullish analysts highlight that Capricor ended 2025 with US$318m in cash, which they view as providing visibility to fund operations through 2027, reducing near term financing risk in their risk adjusted valuation work.
One bullish research view characterizes an 8% share price pullback as a temporary dislocation after an FDA related rally and suggests that short term volatility does not change their longer term thesis tied to deramiocel and Duchenne muscular dystrophy.

Bearish Takeaways

Even within the optimistic research set, there is an implicit caution that recent stock performance has already been strong. This may limit upside if execution on regulatory or commercialization steps does not track current expectations.
Dependence on a single lead asset, deramiocel, and a single core indication is a concentration risk that can affect valuation if the regulatory outcome, label scope or market uptake differs from what bullish analysts are currently assuming.
The focus on a multi billion revenue opportunity, lifelong treatment patterns and survival implications in some research highlights that expectations are already elevated. This can increase the impact of any delay, label restriction or competitive data on future valuation work.
The characterization of an 8% pullback as a healthy correction reflects that volatility is part of the current investment case, and shorter term traders may face sharp moves around news flow and regulatory milestones.

What's in the News

The FDA has resumed review of Capricor's Biologics License Application for deramiocel in Duchenne muscular dystrophy cardiomyopathy, classifying it as a Class 2 resubmission with a PDUFA target action date of August 22, 2026, and Capricor indicates the agency has not identified review issues to date.
Capricor presented additional Phase 3 HOPE-3 data at the 2026 Muscular Dystrophy Association conference, including cardiac MRI findings linked to myocardial fibrosis, a composite Global Statistical Test favoring deramiocel, and functional outcomes such as hand to mouth activity and the Duchenne Video Assessment "eat 10 bites" task.
Further Phase 3 HOPE-3 data were shared at the 2026 American Academy of Neurology meeting, including home based video assessments that indicated slowing of decline in self feeding, a function tied to patient independence.
Capricor has been added to the S&P Biotechnology Select Industry Index, which can influence how index linked funds and benchmarks track the stock.
The Wall Street Journal highlighted that the FDA accelerated approval pathway has become narrower and harder to predict, with fewer accelerated approvals in 2025 compared with 2024 and several recent rejections across rare disease therapies. The report included Capricor among companies operating in this regulatory setting (The Wall Street Journal).

Valuation Changes

Fair Value: The updated analyst fair value moves from $50.80 to $54.67, a modest uplift in the target range being used.
Discount Rate: The discount rate edges higher from 7.04% to 7.14%, indicating slightly more required return in analyst models.
Revenue Growth: The revenue growth input shifts from 176.75% to a very large figure of roughly three times that level, reflecting much stronger modeled top line expansion.
Net Profit Margin: The assumed profit margin rises from 33.40% to 44.64%, pointing to a meaningfully higher earnings contribution on each dollar of revenue in the updated work.
Future P/E: The future P/E multiple increases from 35.57x to 42.95x, indicating a higher valuation multiple being applied to forward earnings assumptions.

24 views

Key Takeaways

Strong pipeline in rare disease therapies and advanced platforms positions Capricor for regulatory support, market demand, and diversified future revenue streams.
Solid financial position and manufacturing readiness reduce dilution risk, enabling quicker commercialization and improved earnings stability.
Reliance on a single late-stage therapy amid regulatory setbacks, rising costs, and increasing competition heightens risks to revenue timing, earnings visibility, and long-term growth.

Catalysts

About Capricor Therapeutics

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.What are the underlying business or industry changes driving this perspective?

The continued rise in the global prevalence of rare and genetic diseases is directly fueling unmet medical needs in areas like Duchenne Muscular Dystrophy (DMD), placing Capricor's Deramiocel in a strong position for regulatory support and future market demand, which could drive substantial revenue growth upon successful approval.
With growing adoption of personalized and precision medicine, Capricor's advanced exosome platform is now in the clinic with StealthX, broadening potential future applications (beyond vaccines) and strategic partnerships, enabling pipeline diversification and supporting future earnings growth and revenue stability.
Increasing healthcare spending in developed markets and the patient-centric focus of recent FDA leadership enhance the probability of reimbursement and broad adoption for therapies like Deramiocel that target high-burden, underserved pediatric diseases, which could improve both top-line revenue and net margins post-approval.
Capricor's strong cash position ($122.8M), combined with the potential to receive a priority review voucher and an $80M milestone payment upon approval, provides a cushion to minimize dilution risk and support commercial launch, which may positively impact future earnings per share and reduce financing overhang.
Advancements in regulatory pathways for rare diseases and cell therapies, along with Capricor's demonstrated manufacturing readiness and quality approvals, set the stage for accelerated approval and commercialization, shortening the path to revenue generation and potentially expanding gross margins earlier than currently reflected in the stock.

Capricor Therapeutics Earnings and Revenue Growth

Capricor Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Capricor Therapeutics currently has no revenue. Analysts are forecasting revenue to reach $245.5 million by April 2029.
As a pre-revenue company, Analysts expect Capricor Therapeutics to achieve a profit margin of 44.6% in 3 years time.
Analysts expect earnings to reach $109.6 million (and earnings per share of $2.08) by about April 2029, up from -$105.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $297.1 million in earnings, and the most bearish expecting $64.6 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 43.2x on those 2029 earnings, up from -17.9x today. This future PE is greater than the current PE for the US Biotechs industry at 16.9x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.14%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The late-stage pipeline remains highly concentrated around Deramiocel for DMD cardiomyopathy, and recent regulatory challenges-including a surprise FDA complete response letter (CRL) and uncertainty around acceptable efficacy endpoints-highlight the risk that any clinical or approval setbacks could result in prolonged revenue delays and reduced earnings visibility.
The company currently generates no commercial revenue and is sustaining high and rising R&D and operating costs ($36.3M R&D spend in H1 2025 versus $21.8M H1 2024, with net loss doubling year-over-year), putting pressure on cash burn and increasing the likelihood of future dilution if regulatory approval or commercial launches are delayed, negatively impacting future earnings per share.
Heightened regulatory unpredictability and shifting FDA guidelines for rare disease and cell/gene therapies-evident in the abrupt change in feedback, advisory committee cancellation, and unclear primary endpoint discussion-expose Capricor to extended approval timelines and potentially greater costs, which risks further delays in market access and revenue realization.
The long-term industry trend of accelerating competition in genetic and regenerative medicine increases the risk that, during Capricor's extended regulatory process, other entrants (especially larger or better-capitalized biopharmas) may develop superior or faster-to-market DMD or cardiomyopathic therapies, potentially eroding Capricor's future market share and revenue potential.
While the exosome platform offers long-term pipeline diversity, it is still in very early clinical stages, faces significant scientific and commercial uncertainty, and has not been a core focus for investment; thus, Capricor remains vulnerable to the risk that if its lead program stumbles, backup revenue streams will take years to materialize, hampering both long-term revenue growth and margin improvement.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $54.67 for Capricor Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $63.0, and the most bearish reporting a price target of just $43.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $245.5 million, earnings will come to $109.6 million, and it would be trading on a PE ratio of 43.2x, assuming you use a discount rate of 7.1%.
Given the current share price of $32.5, the analyst price target of $54.67 is 40.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Capricor Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Future FDA Approvals Will Expand Rare Disease Treatments